Valuation: Valneva SE

Market Cap 490M 549M 456M 414M 780M 52.02B 794M 5.47B 2.14B 27.14B 2.06B 2.02B 86.85B P/E 2026 *
-5.93x
P/E 2027 * 9.36x
Enterprise Value 624M 699M 580M 527M 992M 66.21B 1.01B 6.97B 2.73B 34.54B 2.62B 2.57B 111B EV / Sales 2026 *
4.13x
EV / Sales 2027 * 1.95x
Free-Float
89.26%
Yield 2026 *
-
Yield 2027 * -
1 day+1.93%
1 week+4.02%
Current month-4.61%
1 month-8.37%
3 months+18.74%
6 months-1.26%
Current year-30.47%
1 week 2.5
Extreme 2.5
2.68
1 month 2.42
Extreme 2.418
2.9
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.15
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
1/27/26 A Sell

Chief Technology Officer

11,800 0.0069%
1/26/26 A Sell

Chief Financial Officer

11,800 0.0069%
1/19/26 A Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
+1.93%+4.02%-42.12%-51.61% 549M
+0.21%-4.63%+55.34%+71.32% 68.98B
+1.66%+7.51%+8.12%+60.04% 53.15B
+3.14%+7.17%+12.48%+44.42% 50.83B
+3.45%+4.70%+33.44%+35.96% 44.61B
-2.20%+0.61%+281.88%+532.76% 40.57B
+6.43%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
-3.99%-12.42%+28.64%-3.76% 25.44B
+1.74%-2.02%-13.55%-12.92% 22.66B
Average +1.46%+1.80%+39.42%+83.05% 38.03B
Weighted average by Cap. +1.59%+2.33%+50.88%+103.11%

Financials

2026 *2027 *
Net sales 151M 169M 140M 128M 240M 16.02B 245M 1.69B 660M 8.36B 635M 621M 26.75B 283M 317M 263M 240M 451M 30.07B 459M 3.16B 1.24B 15.69B 1.19B 1.17B 50.2B
Net income -81.11M -90.87M -75.39M -68.57M -129M -8.61B -131M -906M -354M -4.49B -341M -334M -14.37B 53.07M 59.46M 49.33M 44.87M 84.41M 5.63B 85.93M 593M 232M 2.94B 223M 218M 9.4B
Net Debt 134M 150M 124M 113M 213M 14.19B 217M 1.49B 584M 7.4B 562M 550M 23.69B 62.48M 69.99M 58.07M 52.82M 99.37M 6.63B 101M 698M 273M 3.46B 263M 257M 11.07B
Projected Income Statement - Annual - Valneva SE
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
15/10/26 €2.585 +1.93% 233,019
14/10/26 €2.536 +0.16% 229,421
13/10/26 €2.532 -4.20% 263,963
12/10/26 €2.643 +4.34% 338,128
09/10/26 €2.533 +1.93% 327,340
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Valneva SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.585EUR
Average target price
6.193EUR
Spread / Average Target
+139.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Valneva SE